Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Early research (Phase 1)Study completedNCT00545519
What this trial is testing

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Who this might be right for
Relapsed Or Refractory Multiple Myeloma
Washington University School of Medicine 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Testing effectiveness (Phase 2)Ended earlyNCT06351644
What this trial is testing

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Adriana Rossi 2
Testing effectiveness (Phase 2)UnknownNCT04674514
What this trial is testing

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Ascentage Pharma Group Inc. 48
Early research (Phase 1)Study completedNCT02852837
What this trial is testing

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 50
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Not applicableNo Longer AvailableNCT02368301
What this trial is testing

Expanded Access Treatment Protocol CA204-143

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Looking for participantsNCT07227311
What this trial is testing

Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 200
Testing effectiveness (Phase 2)Study completedNCT00448357
What this trial is testing

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 54
Testing effectiveness (Phase 2)Looking for participantsNCT06822972
What this trial is testing

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University 27
Early research (Phase 1)Study completedNCT03309111
What this trial is testing

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA 81
Early research (Phase 1)Study completedNCT00346255
What this trial is testing

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
ImmunoGen, Inc. 37
Early research (Phase 1)Study completedNCT03143985
What this trial is testing

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Koen van Besien 18
Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Testing effectiveness (Phase 2)Looking for participantsNCT06644443
What this trial is testing

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen University General Hospital 10
Early research (Phase 1)Study completedNCT00664898
What this trial is testing

The Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Testing effectiveness (Phase 2)Study completedNCT00429949
What this trial is testing

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Who this might be right for
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Washington University School of Medicine 21
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Very early researchUnknownNCT03661554
What this trial is testing

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma
The Pregene (ShenZhen) Biotechnology Company, Ltd. 15
Next Page